$3.65
-0.015-0.41%
Last update: Nov 6, 4:50 PM
Arbutus Biopharma Corp (ABUS) Stock Price, Quote, News & History
ABUSNASDAQ
The FDA lifts its 3-year clinical hold on Arbutus Biopharma's AB-101 hepatitis B drug candidate, clearing US clinical trials.
You can purchase shares of Arbutus Biopharma (NASDAQ:ABUS) through any online brokerage.
Other companies in Arbutus Biopharma’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Arbutus Biopharma has a consensus price target of $5.50.
The stock price for Arbutus Biopharma (NASDAQ: ABUS) is $3.65 last updated November 6, 2026 at 4:50 PM EST.
There are no upcoming dividends for Arbutus Biopharma.
Arbutus Biopharma does not have any upcoming earnings scheduled.
There is no upcoming split for Arbutus Biopharma.
Arbutus Biopharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can...
